Skip to main content

Market Overview

Publicly-Traded Addiction Treatment Co. Signs Exclusive Licensing Agreement With Alar Pharmaceuticals

Share:
Publicly-Traded Addiction Treatment Co. Signs Exclusive Licensing Agreement With Alar Pharmaceuticals

Addiction treatment company Indivior PLC (NASDAQ: INDV) obtained exclusive global rights to develop, produce and commercialize Alar Pharmaceuticals’ portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting injectable (LAI) candidate, ALA-1000.

"Alar provides Indivior with a unique opportunity to further address unmet patient needs in the treatment of OUD with potentially the first three-month buprenorphine LAI," stated Christian Heidbreder, chief scientific officer. "By providing a therapeutic option for patients who might benefit from less frequent dosing, ALA-1000 has the potential to broaden the spectrum of care for OUD treatment as well as enhance the addressable patient population."

Global Rights

Under the agreement, Indivior will pay $10 million to secure exclusive global rights (except in China, Hong Kong, Taiwan and Macau) to develop, manufacture and commercialize ALA-1000 and Alar's future buprenorphine-based LAI product candidates. The $10 million payment is in addition to an initial $5 million option payment made by Indivior to Alar in Q1. Alar is entitled to potential milestone payments if various developmental, regulatory, and commercial goals are achieved.

ALA-1000 is an investigational drug and is positioned to be the first three-month buprenorphine administered subcutaneously entering the clinical stage. With dosage intervals of potentially up to four times per year, ALA-1000 could address unmet opioid use disorder patient needs with a longer duration of treatment, which could provide an option for patients seeking a less frequent maintenance therapy regimen, for patients living in remote areas without easy access to care, and for high-risk patients, such as those transitioning from the Justice system.

Photo: Courtesy of Louis Reed via Unsplash

 

Related Articles (INDV)

View Comments and Join the Discussion!

Posted-In: Addiction Treatment Alar Pharmaceuticals Christian Heidbreder premiumCannabis News Markets